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~IW, This study attempted to determine her an 
multifocror rtsk reduction pro over 4 
rs would reduce the rate of development of new coronary artery 
Recent an~~~ph~ trials have gtenerally demon- 
t normallnation of plasm0 Ilpoprotein p&iles reduces 
coronary lesions, but limited 
these treatments influence the development of 
. Three budrcd men and women with coronary artery 
randomized to multibctor risk reduction or usual 
slgnilicant improvements in risk factors were 
achieved by the risk reduction group compared with minimal 
by the usual care group. Quantitative coronary angiog- 
raphy was performed on entry and after 4 years under identical 
coudRlons. A decrement in the minimal diameter of visually 
normal segments r0.2 mm was conshlered to indicate new lesion 
fiwmathm, 
The lipid infiltration theory promoted by Duff and McMillan (1) 
in the early 19505 was the basis for numerous large pidemiologic 
investigations thathave linked elevations i  erum cholesterol t  
coronq atherosclerotic disease (2-8). Subsequently, numerous 
trials utilizing clinical end points to assess the eilicacy of lipid 
ment in patients atrisk for (or with overt) coronary artery 
have been performed (4,9-13). Typically, a reduction i
cardiovascular events was obsetved and correlated with a favor- 
in the lipid profile. Both pharmacologic andnon- 
pharmacoh@c intervention trials using angiographic end points 
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&W&S. A total of 1,605 segments, ~~~seatin~ 257 paGents, 
were considered normal at baseline, with 804 and 801 disease-~~ 
segments in the usual care and risk reductigtn gr~aps, rrspcc- 
tively. Ninety-nine segments (6.1%) were idedilicxl by follow~p 
quantitative an~i~~phy and two an~i~~~~bic observers as 
having stew lesion formation (usual care 7.6%, risk reduction 
4.7%, p = 0.05). New lesion formatiun was observed in 41 (31%) of 
131 patients in the usual care group and in 29 (23%) of 126 
patients in the risk reduction group (p = 0.161, with a mean 
number of new lesions/patient of 0.47 in the usual care group and 
0.30 in the risk reduction group (p = 0.06). Multiple regression 
analysis identified on-study dietary Pat intake as the best correlate 
with new lesion formation. 
Coac&&orts. These data indicate that intensive muttifactor risk 
reduction tends to diminish the frequency ol mew coronary lesion 
formation. 
Co@ Cardioll994;24:9QO- 8) 
have since volved (14-Z). These studies consistently revealed a 
positive association between the degree of improvement in he 
lipid profile and angiographic evidence of a decrease in the 
progression f established coronary artery disease. Some studies 
also revealed a significant degree of disease r gression as well 
(14,16,18,21,22,23). 
If lipid infiltration is inciting vascular injury that leads to the 
development of coronary artery disease, intensive management 
of dyslipidemias might be associated with less new lesion 
developmeni. However, relatively few clinical trials designed to
influence the lipid profile have specifically addressed the rate 
of new lesion development asa function of favorable risk 
factor modification for coronary atherosclerosis. To our knowl- 
edge, only the Cholesterol Lowering Atherosclerosis Study 
(CLAS) (24) has reported an effect of a lipoprotein terven- 
tion on the rate of new coronary atherosclerotic lesion devel- 
opment. Also, several studies (25,26) have provided prelimi- 
nary evidence that calcium channel blockers, which do not 
change the lipid profile, may reduce the rate of new lesion 
formation. 
We hypothesized that he incidence ofnew atherosclerotic 
lesions in the coronary vasculature would be reduced signifi- 
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cantly after an i~te~eni~g period of intensive multi 
factor reduction in 
vcntion Project (S 
Stndy ~at~~~ts. The SCRIP study design have been 
described elsewhere (23). In brief, SC Was a ri~~~~~i~e~, 
multiple risk factor intervention trial using angiographic end 
points. It was conducted over 4 years in men and women with 
COKMlilry artcry d&case with the j@ of altering the rate of 
COrOIliUy artery lumen IlilITlWiflg. The p~l~t~ci~~~l~ts were ran- 
domized to the usual CilK of their own physician or to an 
i~~dividu~lli~cd, nudtifirctor, risk reduction program. Tbrce 
hundred paticuts (259 men, 41 women; mean [LSD 
1.4 years) with ~l~~gil~g~ilpi~i~i~lly dCfinCd coronary i 
rosis wcrc randomly assigned to MSIQI cart (n = 155) or 
t~~ultif~ict~)r risk reduction (n = 135). Computer-;lssistcd quan 
titative coronary ~~~teriogri~pl~y was performed at baseline aud 
at 4 years. The study protocol and progress were reviewed 
before the start and annually by the Stanford University Panel 
on Human Subjects in Medical Research, by committees on 
the use of human subjects at each of the participating hospitals 
and by an cxtcrnal Safety and Data Monitoring Committee 
appointed by the National Heart, Lung, and Blood Institute. 
lnformcd consent was obtained from all subjects before study 
enrollment. 
IP risk reduction program. Patients assigned to risk 
reduction were provided individualized programs involving a 
low fat, low cholesterol dist; exercise; weight loss; smoking 
cessation, and medications to favorably alter lipoprotein pro- 
files. All risk reduction group subjects wcrc instructed by a 
dietitian in a low-fat, low-cholesterol and high-carbohydrate 
diet with a goal of ~20% of energy intake from fat, ~6% from 
saturated fat and ~75 mg of cholesterol/day. A physical activity 
program was recommended consisting of an increase in daily 
activities, such as walking, climbing stairs and household 
chores and a specific endurance exercise training program. A 
staff psychologist developed an individualized stop-smoking 
program for smokers in the risk reduction group. A major goal 
was to decrease low density lipoprotein (LDL) cholesterol to 
< 110 mg/dl (2.84 mmol/liter), to decrease triglyceride con- 
centrations ~100 mgldl (1.13 mmol/liter) and to increase 
high-density lipoprotein (HDL) cholesterol concentrations 
>55 mg/dl (1.42 mmol/liter). If the SCRIP staff concluded it 
unlikely that a subject in the risk reduction group would meet 
the maximal LDL cholesterol goals within the first year without 
drug therapy, a cholesterol-lowering drug regimen was added. 
Risk factor evaluations. All subjects had their clinical 
status and risk factors evaluated at baseline before randomiza- 
tion and annually for 4 years. Blood pressure was measured 
three times after a 5-min rest and with the subject seated using 
a HawksLey random-zero sphygmomanometer. Skinfolds were 
measured in triplicate at the subscapula, triceps and suprailiac 
crest and summed to nt general adiposity. Reported 
smoking status was ver measuring the carbon monoxide 
content of expired air n Ecolyzer (27) and the thiocya- 
nate co~ce~tratjo~ in plasma (28). Symptom-limited treadmill 
tCSting was performed using a Balke-type protoco?. 
intake was determined by 4-day food records using the 
ruton Coordinating Center protocols for data collection 
and coding and version 13 data base for data analysis (29). 
Physical activity was reported using the Stanford 7-&y physical 
activity recall (30) and other questions that solicited informa- 
tion on the frequency of participating in specific leisure-time 
and conditioning activities. 
At baseline and annually, fasting concentrations plasma 
lipids and hpoprotcins were measured during two clinic visits. 
The IWO values were averaged for each subject to represent the 
SUI$YJ at basslhc and for each year in the study. Plasma 
cl~ucentratiot~s of total cholcstcrol and triglyccridcs were mea- 
surcd in the Stanford L’ otein Research Laboratory by 
enzymatic proccdurcs (A 00 instrument, Abbott Labora- 
ttmrics) (3 lJ2). Tbc H cbolcstcrol Wits measured by dcxtran 
sulfate-iiiagnesium~i pi pitation (33) followed by enzymatic 
determination of cholesterol. The laboratory remained certi- 
tied by the Ccntcrs for Disease Control and Prevention lipid 
standardization program (34). Lipoprotein(a) concentration 
was measured by an enzyme-linked immunoasay (EL&A) kit 
[ Macra lipoprotein(a), T umo Dianostics Division] described 
previously (3536). The L plus intermediate density lipopro- 
tcin apolipoprotcin B centration was measured by stan- 
dardized ELISA use of of two monoclonal capture antibodies 
(Medix Biotech) (37). Plasma glucose concentration was mea- 
sured using the glucose oxidase method (38) and insulin 
co!. Basclinc coro- 
nary artcriograms wcrc obtained in a uniform manner at 
basclinc and follow-up with the requirement that nitroglycerin 
be administered before coronary injections. Coronary cathe- 
ters with metallic cylindrir: markers near their distal end 
provided a sharp calibration cdgc for quantitation, which 
reduces measurement variation when computer-assisted mea- 
surement techniques are used (40). SCRIP required that 
neither the qualifying segment nor any vessel proximal to it 
contained a lesion ~70% in diameter reduction and that the 
vessel had neither been grafted nor instrumented by a previous 
revascularization procedure. Subjects were eligible for the 
study if at least one major coronary artery showed a segment 
with lumen narrowing between 5% and 69% that was unaf- 
fected by revascularization‘ procedures. Visually normal seg- 
ments (~5% narrowing in lumen diameter) were quantitatcd 
at enrollment; however, these segments were not included in 
the primary analysis of the SCRIP hypothesis. 
All consenting sub,jects had protocol-mandated follow-up 
arteriograms obtained 4 years after the baseline arteriogram. 
Use of marker catheters, before nitroglycerin adminislration 
and replication of projection angles were performed as at the 
baseline study. If a subsequent ‘l-year artCriOgraIII was nOt 
Obtainable, the results of earlier clinically indicated angio- 
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grams were included as long as the interval between the 
-baseline and follow-up angiogram was >12 months and 
the clinic&y indicated angiogram was performed according to
the research protocol. 
The quantitative coronary angiographic FIstem used in this 
study was developed atStanford Medical Center to measure 
coronary vessels on 35mm cineangiograms. Its design, accu- 
racy, precision and intraabserver ;ndinterobserver a iability 
have beer, previous@ reported (4). The system has two tine 
fitm digitizers that simultaneously process paired coronary 
arterjograms for evaluation of serial changes in coronary 
art&s, A pair of video monitors for each projector allow the 
operator real-time viewing c!f the tilm for frame selection. 
Comparable segments on baseline and follow-up angiograms 
were digitized. The operator manually delined approximate 
edges, and an automatic edge-finding algorithm defined 
ent lengths and the margins for measurement of 
mean and minimal diameters. The operator had no knowledge 
lesion &nation in the 
Two experienced angiographic observers 
(with no knowledge of patient randomization assignment) 
visually assessed ach segment that had an interval reduction 
in minimal diameter >0.2 mm within a segment previously 
considered normal. In the SCRIP analysis, ndividual diseased 
segments were categorized asprogressing, :egrcssing orun- 
changed on the basis of whether the minimal diameter of 
diseased segments changed by >O.Z mm. This threshold of 
0.2 mm was based on a threefold multiple of the within- 
procedure measurement variability (SD 0.033 mm) and further 
multiplying bya factor of 2 to account for between-procedure 
variation (40). 
By simultaneous side-by-side comparison, the baseline and 
follow-up angiograms were compared visually. The identical 
projections of the baseline and follow-up angiograms were 
simultaneously displayed on the two monitors. From these 
matched views, the precise frame on which quantitative coro- 
nary edge detection maiysis suggested new lesion development 
for the segment of interest was displayed. Visual assessment 
for interval coronary segment change was based on both static 
imag:s and dynamic display at variable rates to confirm or 
refute serial change. Results of the visual assessment were 
recoded as 2we possible outcomes: no apparent change, 
definite new lesion or previous disease present with progres- 
sion. 
St&tbl analysis. For within-group czrmparisons from 
baseline toon-study, one-sample I tests were used. The signif- 
icance of differences in risk factors or angiographic measures 
between the ususi cm and risk reduction groups or between 
tht: “m new lesion” and “new lesion” groups were determined 
bY two-sample I tests, chi-square or a Wilcoxon test for two 
samples, Per-segment analysis adjusting for within-patient 
correlations for the development of new lesions were per- 
formed by fitting a beta-binominal model (42). Uaivariate and 
~t~ariate logistic regression a alyses were performed to 
determine which body composition, dietary, clinical or labora- 
tory variables wel:e associated with new lesion formation. Body 
composition variables analyzed included weight, relative 
weight, body mass index, skinfolds and waist/Q ratio. Dietary 
variables were total fiber intake (g); soluble fiber intake (g); 
percent of total calories from total fat, saturated fat, monoun- 
saturated fat, polyunsaturated fat and alcohol; polYunsaturat 
edlsaturated fatratio intake; cholesterol intake (andday); and 
calories consumed/kg body weight. Laboratory variables in- 
cluded plasma triglycerides, cholesterol, LDL cholestero!, 
HDL cholesterol, total cholesteroUI-IDL ratio, a~lipoprotein 
B, apolipoprotein(a) and fastingipostprandial glucose and in- 
sulin conce~t~~tio~s. Clinical variables analyzed ~~cl~~ed sys-
tolic and diastolic blood pressure, m~irna~ ~?etabo~ic equiva- 
lents (METS) achieved on treadmill testing and the 
Framingham coronary heart disease risk score (43). Si 
cance was set at p < 0.05. 
esults 
Results af the SCRIP study have been previously reported 
(23). The intensive risk reduction resulted in significant im- 
provements in various risk factors, including LDL cholesterol 
(-23%), HDL cholesterol (+ 12%) plasma triglycerides 
(-20%), body weight (-4%) exercise capacity (+20%) and 
the intake of dietary fat (-24%) and cholesterol (-46%) 
compared with relatively small changes inthe usual care group_ 
The risk reduction group showed a rate of narrowing of 
diseased coronary artety segments that was 47% less than that 
of subjects inthe usual care group (p < 0.02) over the 4 years 
of the studY. There WZF asignificant reduction iothe number of 
cardiac events requiring hospital admission i  the risk reduc- 
tion group relative to the usual cttre group (25 and 44, 
respectively, p = 0.05). 
Of the 300 subjects rartdomized in SCRIP, 274 (91%) 
completed follow-up arteriograms. and 257 (g6%) had com- 
parative measurements of segments that were free of disease at 
baseline and adequately visualized in follow-up. Of the 17 
arteriograms excluded from analysis for technical reasons, 11 
were due to the patients’ failure to follow the nitroglycerin 
protoco! at baseline orfollow-up, 3 to inadequate film quality, 
2 to revascularization procedures that eliminated all eligible 
segments, and 1 to normal SCRIP-eligi’lle s gments. The risk 
intervention a d risk factor status at baseline and on-study for 
the 257 patients included in this report are presented in Table 
1. These 257 subjects had 1,647 corona9 artery segments 
ideatified as visually normal (~5% stenosis) at baseline. Of 
these, quantitative coronary angiography identified 491 seg 
ments that had a >0.2 mm reduction in minimal lumen 
diameter between entry and follow-up angiogiam. Subsequent 
visual assessment of hese segments revealed that, m retro- 
spect, 42 of these segments had previous disease atbaseline. In
the remaining 1,605 visually normal segments, 99new tesiuns 
were identified (Fig. I). Tht: frequency of new lesion formation 
was compared for subjects randomized to usual care versus risk 
reduction on a patient-by-patient a dsegment-by-segment 
basis. 
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s On-Study Risk ~~te~~~t~o~ Values and Risk Factor Measurements for the 
Wsual Care and Risk Reduction Groups (mean values) 
Baseline 
On Study 
RR Change 
UC t RR RR From 
(n = 257) (n ?3l, (n = 126) Baseline (%) 
Dietary saturated fat (% cal) 10.0 IO.6 6.8 -2.9* 
Dietary cholesterol (mg/day) 260 273 142 -94* 
Performance of daily activities 1.78 1.95 2.20 0.46.t 
Current cigwette user (%) 13.7 16.8 10.4 -0.0 
Nypolipidenlic drugs (% patients) 9.0 30.7 03.3 80.7’ 
Body compo&ion 
Weight (kg) 82.0 85.8 77.8 -3.h* 
Body mass index (kg/m”) 27.0 27.5 26.0 -3.3’ 
Blood pressure 
Systolic (mm Hg) I I’).? 121.1 120.4 -0.2 
Dinstolic (mm Clg) 71.3 72.3 hY.6 -1.6 
Exercise lest, fllilR ME’f lcvrl 8.9 9.8 10.4 i 1Y.w 
Lipid pmli!c 
I‘Wli cholesterol (mg/dl) 22Y.S 422.Y l’J5.1 - 16.4’ 
LIIL cMc!itrrol (IllJJI) I56.b 149.6 121.0 -23.5* 
WDL cholesterol (rg/dl) 44.0 44.8 50.‘) +11.0* 
Triglycerides (mgjdl) IS.5 IN.4 128.‘) - 17.3” 
Glrlcose IderilnCc 
Fasting glucose (mg/dl) 104.4 111.1 101.0 -2.8 
i-h postload glucose (mgIdl) 136.7 164.2 137.0 10.7* 
Framingham risk sccre 14.6 14.1 10.8 -26.9* 
‘p < 0.01. tp < 0.05. HDL. = high density lipoprotein; LDL = low density lipoprotein; RR = risk redfiction; UC = 
us&care; maxfyfET = maximal metabolic &$v;lent. 
per-patient al~a~ys~s. The minimal diameters of normal 
segments at baseline that did not develop new lesions were 
2.30 and 2.32 mm for the usual care and risk reduction groqs, 
reslectively (p = 0.70) (Table 2). The baseline minimal 
diameter of normal segments for patients in lthe risk reduction 
group who developed new lesions was significandy smaller 
than for those in the usual care group (2.55 vs. 3.05 mm, p = 
0.01, for rick reduction and usual care, respectively). The 
percent of all subjects (n = 257 [usual cere, n = 131; risk 
reduction, n = 1261) with at least one new lesion was lower for 
the risk reduction group. However, this difference was not 
statistically significant (usual care [n = 41],31.3%; risk reduc- 
tion [n = 29], 23.0%, p = 0.16). The majority of these 70 
patients with new lesions had no more than one new lesion 
identified. The remaining subjects had predominantly two new 
lesions identified, and a small percent had three or four new 
lesions. The average number of new lesions/patient was 0.47 
for the usual care group and 0.30 for the risk reduction group 
(p = 0.06). 
IPer-segment analysis. Ey a per-segment analysis (Table 3) 
adjusted for within-subject orrelation of new lesion forma- 
tion, baseline minimal diameters for diseased and nondiseased 
segments were net significantly different between the usual 
care and risk reduction groups. The percent of all normal 
segments at enrollinent with new lesion formation was signif- 
icantly lower for those subjects participating in the risk reduc- 
tion program than for patients assigned to usual care (usual 
care [n = 61],7.6%; risk reduction [n = 38],4.7%, p = 0.02). 
When the within-patient correlation for new lesion formation 
is taken into account using a beta-binomial mode!, the Ieve! of 
significance increases to 0.05. 
size. With respect o only new lesions, the 
absolute change in minima! diameter was compared for the 
risk reduction group versus usual care group by a segmenr-by- 
segment and a per-patient analysis. Sixty-one new lesions were 
identified in the usual care group, and the mean and median 
reductions in minimal diameter were 0.62 and 0.57 mm, 
respectively (range 0.2 to 1.54) (Table 3). There were 38 new 
lesions identified among the risk reduction group, and the 
mean and median reductions in minimal diameter were 0.69 
and 0.56 mm, respectively (range 0.22 to 4.69). There were no 
significant differences in the degree of mean or median diam- 
eter reduction for the two groups on a per-segment or per- 
patient analysis. 
New lesions and clinical correlates. Clinical correlates of 
new lesion for.mation were assessed using univariate and 
multivariate analysis (Table 4). For the univariate analysis 29 
potentially influential variables were evaluated for association 
with new lesion development. These variables reflect body 
composition, dietary intake, laboratory values and clinical 
variables (see Methods). The extent o which these variables 
discriminated between the development of new lesions versus 
no new lesions was evaluated. These variables were measured 
at baseline and on-study. The on-study values were an average 
of year 1, 2, 3 and 4 annual assessments. First, the usual care 
and risk reduction groups were combined and analyzed for 
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-arysegma 
minimum diameter measu 
uction in minimum diameterby QCA at 
follow-up arteriogram 
191 segments were rfzvicwed for visual 
confirmation of new lesion development 
by co-us of hwo angiographii obs%rvcrs 
blinded to randomization assignment 
prospective categorization 
or not, baWd on il comhinalion of 
~~rn~~lt~~~assi~t~~ ~~~ntitati~)n at 
entry imd 4-ycaf concluding angio- 
grams combined with ViSUilB cot&- 
mation of new lesion development. 
clinical correlates (on a per-patient basis) for the formation of
at least one new lesion versus no new lesions. Diastolic blood 
pressure was significantly lower at entry among patients who 
did not develop new lesions (no new lesions 70.6 mm Hg; new 
lesions 73.1 mm Hg, p = 0.04). Otherwise, there were no 
significant differences at baseline. Analysis of on-study clinical 
variables rwealed significantly lower values in the no new 
lesion category for percent dietary, saturated, monounsat- 
urated and polyunsaturated fat and dietary cholesterol. The 
percent of dietary carbohydrate intake was ignificantly higher 
in the no new lesion category. A reduction i dietary percent 
fat from baseline to on-study was associated with the absence 
of new lesions. A reduction i serum LDL and total cholesterol 
was correlated with no new lesion formation. Reductions from 
baseline toon-study intotal cholesterol, LDL cholesterol, total 
cholesterol/HDL cholesterol ratio, fasting iucose and the 
Framingham risk score were also associated with an absence of 
new lesion development. 
A logistic regression analysis was performed using the 
following variables: on-study smoking rate, dietary cholesterol 
and percent fat; change in LDIJHDL ratio, serum LDL and 
HDL concentrations, diastolic blood pressure and Framing- 
ham risk score. In this analysis no variable had greater 
significance than the dietary percent of calories from fat. The 
coefficients from this analysis ndicate that patients obtaining 
40% of their calories from fat had a 39% chance of developing 
at least one new lesion in the course of 4 years, whereas 
patients who obtained 20% of their calories from fat had a 
19% chance of a new lesion developing. 
The correlation between progression r regression f estab- 
lished coronary artery disease at baseline and the incidence of
new lesion formation was evaluated. In the SCRIP trial, it was 
reported that here were 10.3% of patients inthe usual care 
group versus 20.2% of patients in the risk reduction group in 
the regression category and nearly equal numbers ofpatients 
from both groups in the progression category (usual care 
JACC Vol. 24, No. 4 
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UC RR p Value 
Pts with qualifying angingrams 131 116 
Pas Hiill I-wl kaians II (31X) 3 (23.w;) 0.16 
Mia segment diameter, 3.0s t o.xtt 2.55 r 0.74 0.01 
baseline (mm) 
Min segment diameter, 2.43 ?I 0.80 2.01 1: 0.59 0.01 
follow-up (mm) 
4-year cbangc (mm) - 0.62 i 0.23 -0.51 ? 0.37 0.30 
Median 4-year change (mm) -0.60 -0.46 0.30 
Range in 4-year cbangc (mm) -0.22 to - 1.18 -0.22 to -2.11 
Pts without new lesions 06 97 
Min acgmcnt diamctcr, 2.30 L 0.44 2.32 !I 6.50 0.70 
baschnc (m01) 
IGIl SCglUC~ll diillllrler, 2.26 + h9J 2.2’) 2 0.5 I 0.72 
follow-op (mm) 
-I-year Cllilll~~ (IllIll) - 0.03 2: Il. I I -0.0.3 1 O.IM 0.97 
Pts vvith I ww Icsion 1.1 ?I! 
Pts wilh 2 new Icsions I7 5 O.IlX 
Pts with 23 new Icsions I 2 
/kT;1ge no. or new 1csi0ns’pr O.-l7 fL.10 O.llh 
DaIa nrcscntcd arc taacan ~luc ?SD or nmabcr of paticois (Pts). Mita = 
minimal; pt = patient: other abbrcvia!ions as in Table I. 
49.6%: risk reduction 50.4%) (23). Patients with no change 
represented 19.7% of the usual care group and 17.6% of the 
risk reduction group. Patients with mixed changes represented 
20.5% of the usual care group and 11.8% of the risk reduction 
group. In thts analysis, the presence of new lesions versus no 
new lesions was compared among only those patients with 
progressing disease and those with regressing disease in the 
main SCRIP study. There were 160 patients in the disease 
progression-only and disease regression-only categories. Of 
these patients, 45 developed new lesions, and 115 did not. 
Among the patients who did not develop new lesions, 30 (26%) 
Table 3. Per-Segment Analysis of New Lesion Formation in the 
Usual Care and Risk Reduction Groups 
UC RR p Value 
No. of visually normal segments 804 801 
Segments without new lesions 143 763 
Min segment diameter, 2.2’) 2 0.77 2.28 i: 0.81 0.82 
baseline (mm) 
Min segment diameter, 2.25 i: 0.76 2.24 _f 0.80 0.85 
follow-up (mm) 
I-year change (mm) -0.04 I! 0.28 -0.04 t 0.25 u.93 
Segments with new lesions 61 (7.69) 3s (4.7%) 0.02 
Min segment diameter, 3.03 2 0.77 2.70 2 0.Y I 0.07 
baseline (mm) 
Min segment diameter, 2.40 I 0.75 2.06 2 0.79 0.03 
follow-up (mm) 
4-year change (mm) -0.62 2 0.29 -0.64 2 0.72 0.88 
Median 4-year change (mm) -0.57 -0.52 0.19 
Range in 4-year change (mm) -0.21 to -1.54 -0.22 to -4.69 
Data presented are mean value +SD or number of segments. Abbreviations 
as in Tables 1 and 2. 
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Clinical Correlates of New Lesion For 
sis of Variables ~~~~~fica~t~y Correlated With New 
No New ~1 New 
Lesion Lesion p Value 
Baseline diastolic BP (mm Hg) 
On-study (o/r of calories) 
Pat 
Saturated fat 
Monounsaturated fat 
Polyunsaturated fat 
Carbolaydrate 
On-study dietary chol (mgidl) 
Change from entry to on-study 
5 of dietary fat 
Plasma d10l (mgjdl) 
Total cl1ol/HDL chol 
Ghtcosc, fasting 
Framinghana risk score 
70.6 2 8.9 
27.3 ? 7.9 
8.4 2 3.3 
10.2 z 3.5 
6.5 lr 1.7 
51.5 2 9.6 
196 ? 116.4 
-4.3 2 8.1 
-23.4 + 35.8 
-24.2 rt 33.6 
-0.W + 1.26 
- 0.20 -+ 28. I 
- 2.5 2 4.5 
73.1 r?: 8.4 
30.8 t 9.6 
9.7 + 4.4 
11.6 2 4.0 
7.2 -t 1.7 
47.6 t 10.4 
243 ? 147.0 
-2.1 t 7.8 0.050 
- I I.5 rt 32.4 0.012 
- 12.4 t 28.1 0.005 
-0.53 3- 0.3 0.020 
7.7 + 22.1 0.063 
- 1.3 % 3.5 0.030 
0.04 
0.008 
0.030 
0.0?2 
O(ct6 
0.107 
0.017 
Only variables with p 5 0.05 xc listed. BP = blood pressure; clml = 
chotcstcrol: !-RN_ = high density lipoprotein; LDL = low density lipoprotein. 
were pure regressors, and 85 (69%) were pure progressors. For 
the new lesion group, 7 (16%) were pure regressors, and 38 
(84%) were pure progressors. The difference inthe incidence of
110 IKW lesions and new lesions among patients with only disease 
progression or regression was not statistically significant. 
In SCRIP, differences in rates of change of minimal 
diameter between the usual care and risk reduction groups 
were somewhat greater for women than men, owever, in 
this evaluation there were no significant gender differences 
in the rate of new lesion formation (226 men with 63 new 
lesions [28%]; 31 women with 7 new lesions [23%], 
ation and p~a~~acolo~ic t~~~a~y. The 
acologic influence on the formation of 
new lesions was assessed. Calcium channel antagonists and 
hypolipidemic agents (bile acid sequestrants, lovastatin, gem- 
fibrozil, niacin) were chosen for evaluation. Our analysis was 
based on the administration of one or more of these drugs 
during the fourth year of the study. Ninety-eight subjects 
received calcium channel antagonists, 47of whom were in the 
usual care group and 51 in the risk reduction group. Twenty-six 
percent of the drugs were of the dihydropyridine class. Of 
these 98 subjects, 27 (28%) developed new lesions compared 
with 27% of subjects not taking calcium blocking 
(p = NS). 
One hundred forty-three patients were taking hymlipi- 
demic drugs, 35 of whom were in the usual care group 
in the risk reduction group. Thirty-eight percent of the 
were taking niacin; 67% were taking bile acid-binding resin; 
and 41% were taking an HMG-CoA reductase inhibitor. Of 
these 143 subjects, 29 (20%) developed new lesions compared 
with 41 (36%) not taking hypolipidemic drugs (p < 0.01). 
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ht,s &new Ie&u~ fonnstioa. In this study, coronary artery 
segments that were visually normal on entry developed angio- 
graphic evidence of new atherosclerotic lesions at a signifi- 
mtly lower rate in patients in the risk factor reduction group 
than in those in the usual care group (rate of new lesion 
formation: usual care 7.6%, risk reduction 4.7%, p = 0.05). On 
a per-patient basis there was a trend favoring fewer new lesions 
among those in the risk reduction group; however, it was not 
smtis&Ily significant (for patients with new lesions, usual care 
312, risk reduction 23%, p = 0.16). This could be explained by 
tk substantial difference in statistical power for the two types 
of analyses (for per-segment analysis, n = 1,605; fur per- 
pticnt analysis, n = 257). 
Fur the purpose of this study, new lesion formation was 
defined as a decrease in minimal diameter of a prcdelined 
coronary artery segment >0.2 mm and confirmed on visual 
assessment as representing a lesion. inherent limitations of 
angiography, however, preclude s ly labeling these seg- 
ments as normal at baseline, Theoretically and very likely, 
concentric atherosclerotic disease or minimal focal disease, 
whiih tends to be concentric and thus not readily detectable as 
a lumen irregularity on arteriography, may not have been 
recognized at enrollment. Thus, this analysis may have as much 
to do with disease progression of small lesions as it does with 
the formation of new lesions. The use of intravascular ultra- 
sound in future studies of new lesion formation should help to 
alleviate this problem. However, there is no obvious reason 
why the usual care or risk reduction groups would be dispro- 
portionately affected by these limitations in angiographic de- 
tection of atherosclerotic disease. Therefore, we conclude that 
the somewhat lower rate of new lesion formation for the 
coronary segments exposed to intensive risk fnctor intervention 
does signify a decrease in atherogenesis. 
New Icsbns &I&XII amelates. Combining the risk 
reduction and usual care groups, and comparing baseline 
charncteristics for those who developed new lesions versus 
those who did not, revealed similar profiles. Among the 29 
variables assessed, only diastolic blood pressure differed sig- 
nikantly between the two groups. It is unlikely that this 
relatively small baseline difference in diastolic blood pressure 
(2.5 mm Hg, p = 0.04) significantly influenced the rate of new 
lesion formation. The on-study differences in diastolic blood 
pressure were also different between those subjects with and 
without new lesions (2.3 mm Hg, p = 0.04). This relation 
between diastolic blood pressure and new lesion formation in 
SCRIP is similar to the relation of blood pressure change 
produced by nicardipine and new lesion formation reported by 
Waters et al. (25). 
The a priori hypothesis states that multiple risk factor 
intervention would result in a diminished rate of new lesion 
formation. All variables that differed significantly for no new 
lesion and new ksion groups were consistent with the study 
hypothesis This study showed a strong correlation between 
on-study dietary fat (percent total, saturated, monounsat- 
urated and poiyunsaturated fat), cholesterol intake and the 
incidence of new lesion formation. Furthermore, reductions in 
dietary cholesterol and total fat intake, serum LQL and total 
cholesterol concentration, total ~holesterol~DL cholesterol 
ratio and fasting glucose concentrations correlated with t 
absence of new lesion formation. A stepwise logistic regression 
analysis assigns the difference in new lesion formation predom- 
inantly to the percent of calories consumed as fat. This relation 
of dietary fat intake to new lesion fo~ati~~ is consistent with 
the results from the only other published data on new lesion 
formation in an angiograp~i sed trial (Ch~lester~~l Low- 
ering Atb~ro~~~r~~sis Study 
quartile of increased consu 
fat was associated with a sign& 
developing new lesions. Placebo recipients in the 
whom new lesions did not develop i~~~~~~s~~ dietary pro&in to 
compensate for reduced intake of fat by substituting low fat 
meats and dairy products for kigh fat meats and dairy produets. 
Similarly, SCRIP participants randomized to the risk reduction 
group preferentially increased ~ar~hydrat~ intake to &et 
caloric deficits induced by dietary fat restriction. 
Confounding issues pertinent to the association of no new 
lesion formation and dietary fat intake were assessed. Body 
ition, Framingbam risk score, 
regression analysis confirms the potent effect that dietary fat 
intake had on new lesion formation. Speculation exists with 
regard to potential mechanisms of coronary atherogensis in- 
duced by dietary fat intake t at arc not reflected in the 
standard lipid profile. Dietary fatty acids have been shown to 
influence a variety of arterial wall processes, such as endothe- 
lial permeability, thrombosis and inflammatory responses 
(44,45). Results of this study and those from CLAS demon- 
strate that a reduction in dietary fat intake decreases the rate 
of new lesion formation by mechanisms not limited to LDL 
reduction. 
New Iesion fu~ation and pharm~~Iu~ic therapy. Anti- 
atherosclerotic effects of calcium channel blockers have been 
hypothesized, and incidence of new lesions has been reported 
in animals and randomized, placebo-controlled intervention 
trials using these agents (25,26). Although the overall progres- 
sion of coronary artery disease was not influenced, nifedipine 
and nicardipine have been shown to decrease the rate of new 
lesion development or the progression of minimally diseased 
segments (25.26516-50). In this study, we assessed the fre- 
quency of new lesion formation as a function of calcium 
channel antagonist or hypolipidemic drug administration dur- 
ing the fourth year. For calcium channel antagonists there was 
no significant difference or trend that suggested an influence 
on new lesion formation. Possible explanations for this lack of 
association include a differential effect among calcium channel 
antagonists, insufficient sample size, insufficient duration of 
drug administration and no cause-and-effect relation. 
Administration of one or more hypolipidemic agents during 
the fourth year was associated with a significant reduction in 
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